Real-World Clinicopathological Characteristics, Metastatic Distribution, and Treatment Patterns of Triple-Negative Breast Cancer: A Single-Institution Experience from Nigeria
This retrospective study of 869 Nigerian women with triple-negative breast cancer reveals a predominance of advanced-stage presentation and lung-predominant metastases, with higher tumor grade identified as an independent predictor of advanced disease, highlighting the urgent need for earlier diagnosis and strengthened multidisciplinary management in resource-constrained settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Breast cancer is not a single disease but a collection of different conditions, each behaving in its own way. Some types grow slowly and respond well to hormones, while others are aggressive and do not. Among the most challenging forms is triple-negative breast cancer. This name comes from the fact that the cancer cells lack three specific receptors that doctors usually look for: estrogen, progesterone, and HER2. Without these receptors, the cancer cannot be treated with hormone therapies that work for other types, leaving chemotherapy as the main tool to fight it. This form of the disease is known to be particularly aggressive, often spreading quickly to other parts of the body. In many parts of the world, especially in Africa, women face a heavier burden from this disease, often diagnosed when it has already spread, making treatment much harder. Understanding exactly how this cancer behaves in specific populations is crucial for saving lives, yet detailed information from many regions remains scarce.
A team of researchers in Nigeria set out to fill this gap by looking closely at nearly nine hundred women treated at a major cancer center in Lagos. They gathered information from medical records spanning several years to build a clear picture of who these patients were, how their cancer looked under a microscope, where it had spread, and what treatments they received. The study focused on women with confirmed triple-negative breast cancer, tracking everything from their age and background to the specific stage of their disease when they first arrived for care. The goal was to move beyond general statistics and understand the real-world experience of patients in this setting, identifying patterns that could help doctors catch the disease earlier and treat it more effectively.
The researchers found that the women in this group were, on average, in their early fifties, though the ages ranged widely from young adults to the elderly. Most of the patients were married and employed, coming largely from the southwestern part of Nigeria. When doctors examined the tumors, they saw that the vast majority were a specific type known as invasive ductal carcinoma, which starts in the milk ducts. The cancer cells were also mostly high-grade, meaning they were growing and dividing very rapidly. Perhaps most striking was the stage at which these women were diagnosed. More than three-quarters of the patients already had advanced disease when they first presented to the hospital. Only a small fraction were found to have cancer that was still confined to the breast. This late discovery is a critical problem, as it limits the options for curative treatment.
When the cancer had spread to other parts of the body, it showed a distinct pattern. Among the women with the most advanced disease, the lungs were the most common place to find new tumors, followed closely by the bones. The liver and brain were also frequent sites of spread. This preference for the lungs and other internal organs is different from other types of breast cancer, which tend to spread more often to the bones alone. The study confirmed that this aggressive behavior is a hallmark of triple-negative breast cancer in this population. In terms of treatment, the majority of women received chemotherapy, and a significant number underwent surgery, though most of these surgeries involved removing the entire breast rather than just the tumor. Radiation therapy was also used frequently, often targeting the chest wall or specific areas where the cancer had spread.
One of the most important findings of the study was the link between how the cancer looked under a microscope and how advanced it was when found. The researchers discovered that the grade of the tumor was a powerful predictor of the stage. Women with the highest grade tumors were far more likely to have advanced disease than those with lower grade tumors. This connection held true even when the researchers accounted for other factors like age, marital status, or family history. Interestingly, family history did not appear to be a strong independent factor in this group, which the authors suggest might be because genetic testing is not widely available in the region, meaning many hereditary cases go undetected. The study also noted that while the cancer is often associated with younger women, a large portion of the patients in this group were actually post-menopausal, suggesting that the disease affects women across a broad age range in this population.
The researchers acknowledged that their study had limits. Because it was based on records from a single large hospital, it might reflect the experience of patients who are referred there for complex care, rather than the experience of all women in the country. Additionally, the study did not include long-term survival data, as that information was still being collected at the time of the analysis. Despite these constraints, the work provides a vital snapshot of the current reality for women with triple-negative breast cancer in Nigeria. It highlights the urgent need for better early detection systems and more comprehensive staging to catch the disease before it spreads to the lungs and other vital organs. By understanding these patterns, doctors can work toward strategies that improve outcomes for women facing this aggressive form of cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.